31085 Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials

Abstract

Introduction: Speed of clinical response is an important treatment goal for patients with plaque psoriasis. We examined how early clinical response translated into cumulative health-related quality of life (HRQoL) benefits in patients with moderate to severe plaque psoriasis treated with bimekizumab (BKZ) over 1 year. Methods: Data were pooled for patients randomized to BKZ 320 mg every 4 weeks (wks)(Q4W) in BE SURE, BE READY, and BE RADIANT. Through Wks16–48, data were combined for both BKZ maintenance doses (BKZ 320 mg Q4W and Q8W). The proportions of patients achieving DLQI0/1 (no effect of skin disease on patient’s life) are reported at Wk4 by PASI90 status; cumulative HRQoL benefits through 48 wks were estimated using total area under the curve (AUC0–48) for patients achieving DLQI0/1 by Wk4 PASI90 status. Missing data were imputed as nonresponse (NRI). Results: At Wk4, 352/880 (40.0%) patients achieved PASI90. 57.4% of Wk4 PASI90 responders achieved DLQI0/1, compared with 40.5% of Wk4 PASI90 nonresponders. Total AUC0–48 for achievement of DLQI0/1 was greater in Wk4 PASI90 responders vs Wk4 PASI90 nonresponders: 3664 vs 3263. Patients who achieved PASI90 at Wk4 achieved DLQI0/1 for a greater number of days throughout the 48-wk trial compared with patients who did not achieve PASI90 at Wk4: 256 vs 228 days. Conclusions: BKZ demonstrated fast skin clearance. Early treatment response on BKZ translated into cumulative benefits in HRQoL: Wk4 PASI90 responders achieved DLQI0/1 for a greater number of days during the 48-wk trial than Wk4 PASI90 nonresponders.